The commercial availability of plant-based phytochemical components used in GLP-1 inhibition for the treatment of type-2 diabetes

Abstract

Aim of the study

The objective of this review is to evaluate the commercial availability and therapeutic potential of plant-based phytochemical components that enhance using GLP-1 reduction to treat type 2 diabetes. This work explores their conventional uses, pharmacological effects, and mechanisms of action in modulating GLP-1 inhibition, aiming to expand knowledge on their role in diabetes management.

Materials and methods

A literature review involving international and domestic databases was conducted to identify existing research on plant-based compounds that stimulate GLP-1 inhibition. Data on the availability of these formulations in the market, their ethnopharmacological applications, and their phytochemical composition were gathered and analyzed.

Results

The review identified several plant-derived compounds with GLP-1-stimulating properties, including berberine, curcumin, resveratrol, quercetin, and flavonoids, which have demonstrated the potential to enhance insulin secretion and improve glucose homeostasis. Many of these bioactive compounds are commercially available as herbal supplements or integrated into anti-diabetic formulations. Some formulations have shown greater efficacy and safety than others and have undergone clinical evaluations for diabetes management.

Conclusion

Plant-based GLP-1 inhibition offers promising alternatives for type 2 diabetes treatment. However, challenges such as phytochemical variability, extraction complexity, low bioavailability, and stability issues hinder their synthesis and large-scale production. Advanced techniques are required to enhance formulation, standardization, and commercialization. Addressing these challenges is essential to ensuring consistency, efficacy, and broader application, particularly in resource-limited settings.